Background: Atrial Fibrillation (AF) is characterized by structural remodeling, contractile dysfunction and AF progression. HDACs influence acetylation of both histones and cytosolic proteins, thereby mediating epigenetic regulation and influencing cell proteostasis. As the exact function of HDACs in AF is unknown, we investigated their role in experimental and clinical AF models. 
INTRODUCTION
Atrial Fibrillation (AF) is the most common persistent clinical tachyarrhythmia and a significant contributor to cardiovascular morbidity and mortality. 1 AF is progressive in nature because of atrial remodeling, which provides a further substrate for the arrhythmia. As the expansion of the AF substrate is not addressed by current drug therapies, the likelihood of conversion to sinus rhythm declines with persistence of the arrhythmia. 1 Thus there is a need for treatments limiting or reversing the cellular substrates for AF, i.e. the molecular changes that cause structural remodeling and drive the development and progression of the arrhythmia. 2 Identification of druggable targets in these pathways comprises an initial step towards such "upstream therapy". 3 Several observations suggest a prominent role for epigenetic regulation in the promotion of AF. Epigenetic regulation refers to processes that influence the packaging and/or processing of nuclear DNA, thus controlling the on/off states of multiple genes with discrete switches. Epigenetic regulation thus profoundly affects cellular proteostasis, i.e. the homeostasis of protein production, degradation and function. 4, 5 Derailment of proteostasis has been implicated in the pathogenesis of multiple diseases, including cardiovascular disorders. 5 Importantly, the packaging of chromatin is largely dependent on the acetylation status of histones 6 , which is controlled by histone acetyl transferases and deacetylases (HATs and HDACs, respectively). Evidence for epigenetic regulation in AF originates from observations that the (re)activation of the fetal gene program in cardiomyocytes promotes AF. 7, 8 Furthermore, genetically modified mice with increased HDAC activity are prone to develop atrial arrhythmia and reveal substrates for AF, such as a reduction in connexin 40 expression, cardiac hypertrophy and fibrosis. 9 Thus, HDACs substantially affect cardiomyocyte proteostasis and may participate in AF progression. HDACs affect not only the protein acetylation status of histones, but also target many cytoplasmic proteins, including structural proteins such as -tubulin. [10] [11] [12] Alpha-tubulin is a key component of the microtubule network and its acetylation influences microtubular composition and organization, thereby modulating Ca 2+ signaling and contractility. 13, 14 Thus, acetylation of α-tubulin may represent a second mechanism by which HDACs influence cardiomyocyte proteostasis and AF progression. 5 Recently, progress has made in understanding the crucial role of HDACs in cardiac development and pathogenesis. 4, 15 Eighteen mammalian HDACs are classified into four groups based on their structure, complex formation and expression pattern: Class I (HDAC1, 2, 3 and 8), class IIa (HDAC4, 5, 7 and 9), class IIb (HDAC6 and 10), class III (Sirt1 to 7) and class IV (HDAC11). 4 Several HDAC inhibitors reveal promising therapeutic effects as they attenuate cardiac hypertrophy, fibrosis and contractile dysfunction in mice atria. 4, 9 However, the specific HDAC(s) that contribute to the development of a substrate for AF is/are still unknown. The aim of the present study was to identify HDACs involved in the structural and functional remodeling in AF, with the use of cellular and in vivo experimental models, as well as atrial-tissue samples from AF-patients.
MATERIALS AND METHODS
This section contains a brief summary of the principal methods. For details, see Supplementary data.
HL-1 cardiomyocyte model
HL-1 cardiomyocytes derived from adult mouse atria were obtained from Dr. William Claycomb (Louisiana State University, New Orleans, LA, USA) and cultured as previously described. 16, 17 The cardiomyocytes were normal paced (1Hz) or tachypaced (5Hz) with a CPace100 TM -culture pacer (IonOptix Corporations). Ca 2+ transient (CaT) measurements were performed as previously described. 16, 17 Before pacing, HL-1 cardiomyocytes were treated with HDAC inhibitors described in Table 1 . All inhibitors were obtained from Sigma. The non-active analogue niltubacin (1 µmol/L) was added as a control for tubacin. To study the effect of HDAC6 on CaT, HL-1 cardiomyocytes were transfected with pcDNA3.1+ (empty plasmid), HDAC6 wild type (wt), HDAC6 mutant in the first catalytic domain (HDAC6 m1), HDAC6 mutant in the second catalytic domain (HDAC6 m2), or HDAC6 mutant in both domains (HDAC6 m1-2), by the use of Lipofectamine 2000 (Invitrogen). The HDAC6 plasmids were a kind gift from Dr. Alexander Bershadsky. 
Drosophila stocks, tachypacing and heart wall contraction assays
Wild type W1118 strains were obtained from Genetic Services Inc., Massachusetts. All flies were maintained at 25 o C on standard medium. After fertilization, adult flies were removed and HDAC inhibitors (Table 1) were added into the medium containing fly embryos (Figure 2 A I) . After 2 days, pre-pupae were selected for tachypacing as previously described. 18, 19 Briefly, transparent pupae were placed on 1% agarose gel in PBS (Figure 2 A II). Groups of 5 pupae were subjected to tachypacing (4Hz, 20 min) by the use of a CPace100™-Culture Pacer (IonOptix Corporation). Before and after tachypacing, movies of whole pupae visualized through a microscope at 10x magnification were obtained in triplicate periods of 10 seconds. Heart wall contractions were analyzed using image J software.
Canine model
Animal 
Atrial cardiomyocyte isolation
After electrophysiological study, the heart was excised and immersed in oxygensaturated Tyrode solution (in mmol/L NaCl 136, KCl 5.4, MgCl2 1, CaCl2 2, NaH2PO4 0.33, HEPES 5 and dextrose 10, pH 7.35 by NaOH). The left atrium (LA) was isolated from the heart with intact blood supply and used to isolate cardiomyocytes as described in Supplementary data.
Ca 2+ imaging and cellular contractility assessment
Atrial cardiomyocytes were incubated with indo-1 AM (5 μmol/L, dissolved in pluronic F-127 2.5 μg/ml in 20% DMSO) for 8 minutes followed by perfusion with Tyrode's solution containing 1.8 mmol/L Ca 2+ for 40 minutes before measurement. An integrated system (IonOptix Corporation, Milton, MA) with a video-based edge-detection device and dualexcitation fluorescence photomultiplier was used to monitor Ca 2+ transients and cellcontractility. Further experimental details are mentioned in Supplementary data.
Cell Electrophysiology Recordings
The whole-cell perforated-patch technique was used to record APs at 37°C and 1 Hz in current-clamp mode and tight-seal patch-clamp to record currents in voltage-clamp mode at 37°C as described in the Supplementary data. Clampfit 9.2 (Axon), GraphPad Prism 5.0, and Origin 5.0 were used for data analysis.
Patients
Prior to surgery, one investigator assessed patient characteristics (Table 2) as described before. 17 RA and LA appendages (RAAs and LAAs, respectively) were obtained from patients with paroxysmal (PAF) and permanent AF (PeAF) and control patients in sinus rhythm (SR). The PeAF and PAF group included patients with lone AF or AF with underlying mitral valve disease (MVD). After excision, atrial appendages were immediately snap-frozen in liquid nitrogen and stored at −80°C. The study conforms to the principles of the Declaration of Helsinki. The Institutional Review Board approved the study, and patients gave written informed consent. Tissue was used to perform various assays. Unfortunately, the tissue yield per patient was insufficient to perform all the assays on each patient sample.
However, at least n=3 samples per group were used for the individual tests, as indicated in the legend section. 
HDAC and HDAC6 TDAC domain activity measurements
The overall HDAC activity was measured by utilizing a fluorimetric HDAC activity assay kit (Sigma) according to the manufacturer's instructions (for details see Supplementary data). The HDAC6 activity assay was developed as previously described with minor changes. 20 Atrial tissue samples were lysed in non-denaturing buffer (CelLytic™, Sigma)
supplemented with protein inhibitor cocktail (Roche). HL-1 cardiomyocytes and cardiomyocytes isolated from dogs were lysed in PBS (pH7.4) containing 0.5% Triton X-100 and protein inhibitor cocktail (Roche), followed by sonification and centrifugation. Background signals were subtracted. To correct for quenching of the AMC signal by colored tissue extracts, an additional reference set of samples and buffer blanks with AMC (Alfa Aesar, 5 μl of 80 μmol/L stock) instead of substrate was included. The reference AMC signals were used to calculate quenching ratios relative to the AMC buffer blank signal. Each raw fluorescence value from the substrate-containing samples was divided by the corresponding quenching ratio, followed by subtraction of the substrate background. HDAC6 TDAC domain activity was calculated as the amount of HDAC activity blocked by tubacin.
Protein extraction and Western blot analysis
HL-1 or dog cardiomyocytes or tissue samples were lysed in RIPA buffer as described before. 17 In short, equal amounts of protein were separated on SDS-PAGE gels, transferred onto nitrocellulose membranes and probed with anti-acetylated α-tubulin (Sigma), anti-α-tubulin (Sigma), anti-human HDAC6 (Cell Signaling), anti-mouse HDAC6 (Cell Signaling), anti-HA tag (Sigma) or anti-GAPDH (Fitzgerald). Blots were subsequently incubated with HRP-conjugated anti-mouse or anti-rabbit secondary antibodies (Dako). Signals were detected by the ECL-detection method (Amersham) and quantified by densitometry (Syngene, Genetools).
Polymerized and depolymerized α-tubulin fractions and drug treatment
Polymerized and depolymerized (soluble monomers) α-tubulin were fractionized as previously described with minor changes. 21 In brief, after one rinse in PBS, HL-1 cardiomyocytes were washed in microtubule-stabilizing buffer (MSB) (0,1 mol/L PIPES, pH 6.93, 1 mmol/L EGTA, 1 mmol/L MgCl2, 2 mol/L glycerol) and then incubated for 3 minutes with 0.5 ml MSB containing 0.5% Triton X-100 and protein inhibitor cocktail (Roche). After incubation, the supernatant contained the soluble depolymerized α-tubulin fraction and was transferred to a new tube. The remaining HL-1 cardiomyocytes were washed once with MSB buffer and then lysed with RIPA buffer. The collected lysate contains the polymerized tubulin.
For testing the effect of drugs on (de-)polymerization status of α-tubulin, 20 μmol/L calpain inhibitor, PD150606 (Calbiochem), was added to HL-1 cardiomyocytes 2 hours prior to tachypacing as described before.
17 HDAC6 inhibitor, tubacin (1 μmol/L), was added to cells 12 hours prior to tachypacing. HL-1 cardiomyocytes were tachypaced for 8 hours,
followed by isolation of polymerized and depolymerized α-tubulin fractions as described above.
Statistical analysis
Results are expressed as mean ± SEM. Biochemical analysis were performed at least in duplicate. Multiple-group comparisons were obtained by ANOVA, with one-way ANOVA for non-repeated measurements and two-way ANOVA for repeated-measurement analyses. Individual group-mean differences were evaluated with Student's t-test and Bonferroni correction. Correlation was determined using the Spearman correlation test. All Pvalues were two-sided. P<0.05 was considered statistically significant. SPSS version 20 was used for all statistical evaluations.
RESULTS

HDAC6 and sirtuins mediate tachypacing-induced contractile dysfunction in cardiomyocytes and Drosophila.
HDAC6 inhibition protects against AF 71 Table  1 . *P<0.05 vs control.
We initially determined which HDAC classes were involved in cardiomyocyte remodeling by utilizing various HDAC inhibitors in tachypaced HL-1 cardiomyocytes and Drosophila ( Table 1) . Inhibition of HDAC6 by tubacin and of sirtuins by nicotinamide protected against the tachypacing-induced reduction of CaT ( Figure 1A , B). In contrast, niltubacin (the inactive analogue of tubacin), and the pan-HDAC inhibitors, TSA and sodium butyrate, did not protect from CaT loss, despite reducing overall HDAC activity ( Figure 1C , D). These findings indicate that HDAC6 and sirtuins are involved in tachypacing-induced remodeling in the in vitro HL-1 cardiomyocyte model. To extend these findings to a second experimental model, similar experiments were conducted in tachypaced Drosophila. 19 Tachypacing induced a marked reduction in contractility in non-treated Drosophila ( Figure  2A HDAC6 and sirtuin inhibitors protect against tachypacing-induced contractile dysfunction in the heart wall of Drosophila melanogaster. A) (I) HDAC inhibitors were added to the food and pre-pupae were selected for normal (NP) or tachypacing (TP) (arrows). (II) Pre-pupae were subjected to tachypacing by placing them on an agarose gel connected to electrodes, followed by monitoring of the heart wall contraction rate. (III) Representative heart wall contractions monitored before TP, during TP and after TP with or without pre-treatment with TSA, sodium butyrate (SoBu), nicotinamide (Nic), or tubacin at concentrations as indicated in Table 1 . B) Quantified data showing heart wall contraction rates each from groups as indicated. ***P<0.001 vs control before TP; #P<0.01 vs control TP, n=9-18 pupae for each group.
Tubulin catalytic domain (TDAC) of HDAC6 modulates the loss of CaT and microtubule network through deacetylation of α-tubulin
As tubacin inhibits HDAC6 by blocking the TDAC domain of HDAC6 11 and protects against tachypacing-induced contractile dysfunction in both tachypaced HL-1 cardiomyocytes and Drosophila, we investigated whether HDAC6 becomes activated by tachypacing. A significant increase in HDAC6 TDAC domain activity and HDAC6 expression ( Figure 3A , B) was observed after 6 and 8 hours of tachypacing HL-1 cardiomyocytes. To further support HDAC6 involvement, dominant negative HDAC6 mutants with disrupted catalytic domains were studied. Successful transfection of the various constructs was assessed by Western blot ( Figure 3C ). HL-1 cardiomyocytes transfected with the control plasmid, wild-type HDAC6, or disruption of the first catalytic domain of HDAC6
(HDAC domain) continued to show significant reductions in CaT after tachypacing ( Figure  3D , E). In contrast, disruption of the second catalytic domain (TDAC domain) of HDAC6, or both HDAC and TDAC domains, rescued tachypaced HL-1 cardiomyocytes from CaT loss ( Figure 3D , E). This finding demonstrates that tachypacing-induced CaT reduction is mediated by the TDAC activity of HDAC6. Since the TDAC domain of HDAC6 conveys the deacetylation of α-tubulin 11 , the expression of acetyl -tubulin over the time-course of tachypacing was determined.
Tachypacing caused a significant reduction in α-tubulin acetylation after 6 hours ( Figure 4A , B), which was followed by a significant reduction in total α-tubulin levels after 8 hours Alpha-tubulin, together with β-tubulin, forms the microtubule network, which are structural polymers supporting the architecture, contractile function and the active transport of cytoplasmic constituents, including mitochondria and endoplasmic reticulum.
5,22
Moreover, HDAC6-induced deacetylatation of -tubulin results in the depolymerization of microtubules 12, 23, 24 , and thereby impairs CaT. 14 To examine whether tachypacing-induced HDAC6 activation causes CaT loss via depolymerization of microtubules, HL-1 cardiomyocytes were stained for α-tubulin and acetyl α-tubulin and the structure of microtubules was determined in cardiomyocytes treated with or without tubacin.
Tachypacing significantly reduced the amount of total α-tubulin and acetyl α-tubulin, an effect prevented by tubacin ( Figure 5A , B). In addition, tachypacing significantly reduced the amount of polymerized microtubules, indicating disruption of the microtubule structure ( Figure 5A , B). Finally, tubacin protected against tachypacing-induced depolymerization of microtubules ( Figure 5A , B). The polymerization of α-tubulin was assessed by separation of polymerized from depolymerized microtubules in control and tachypaced HL-1 cardiomyocytes. Similar to confocal experiments, tubacin attenuated the tachypacinginduced reduction of polymerized and depolymerized -tubulin ( Figure 5C ). These observations demonstrate that tachypacing induces deacetylation and depolymerization of -tubulin, and subsequent disruption of the microtubules. Although acetylated α-tubulin is a substrate for both HDAC6 and Sirt2, the sirtuin inhibitor nicotinamide did not prevent 
Tachypacing induces calpain-mediated degradation of depolymerized α-tubulin
The Ca 2+ dependent protease calpain is known to degrade depolymerized but not polymerized -tubulin. 25 Since we previously demonstrated a key role for activated calpain 
HDAC6 inhibition by tubastatin A protects against AF-related remodeling in dogs
To obtain proof of concept that HDAC6 inhibition protects against AF remodeling in vivo, dogs subjected to 7 days of ATP were treated with the HDAC6 inhibitor tubastatin A 
DISCUSSION
Here, we identify HDAC6 as a potentially key enzyme in the development of the substrate underlying AF progression. Tachypacing of HL-1 cardiomyocytes increases HDAC6 activity and expression, resulting in TDAC-domain dependent deacetylation/depolymerization and calpain-mediated degradation of α-tubulin with subsequent disruption of the microtubule network. HDAC6 inhibition by tubacin conserved the microtubule structure and prevented depolymerized α-tubulin from degradation by calpain. Ultimately, this derailment of α-tubulin proteostasis causes contractile dysfunction (proposed model in Figure 7G ). Consistent with our experimental data, patients with PeAF show increased HDAC6 TDAC domain activity and expression, and increased deacetylation and degradation of α-tubulin, which inversely correlates with calpain activity. Finally, in vivo HDAC6 inhibition by tubastatin A protected against atrial remodeling in a dog model of AF.
Together, our results identify inhibition of the TDAC domain of HDAC6 as a promising upstream therapeutic target to conserve α-tubulin proteostasis and attenuate cardiomyocyte remodeling in AF.
Prominent role for HDAC6 in AF-induced loss of proteostatic control
The current study identifies HDAC6 as the most prominent HDAC in AF and a key enzyme in the derailment of the proteostasis that underlies structural and functional remodeling and AF progression.
3 HDAC6 is a member of the class IIb HDACs and is essentially cytoplasmic. 27 HDAC6 deacetylates α-tubulin 10 , which impairs control of cell proteostasis by depolymerization of the microtubule network. 12, 23, 24 , but also in cancer. 30 Furthermore, HDAC6 is the only cytosolic HDAC with two catalytic domains. 31 The second domain is mainly responsible for its TDAC activity. 4, 32 Several lines of evidence suggest that HDAC6 promotes AF by deacetylation of α-tubulin. First, tachypacing-induced remodeling was prevented by treatment with the specific HDAC6 inhibitor tubacin, a drug mainly inhibiting the TDAC domain of HDAC6. 11 In accord, we found that tubacin exclusively changed acetylation status of α-tubulin, without effect on overall protein or histone acetylation. Others have also shown that HDAC6 inhibition by tubacin increases the acetylation of α-tubulin. 23 Secondly, dominant negative mutation of the TDAC domain of HDAC6, the domain conveying the deacetylation of α-tubulin, prevented tachypacing-induced reduction of CaT, while dominant negative mutation of its histone acetylating domain was without protective effect. In accordance with these findings in experimental AF, we found increased TDAC activity of HDAC6 in patients with PeAF to coincide with deacetylation of α-tubulin.
In addition, we identified depolymerization of the microtubule network as the likely downstream step conveying the action of tachypacing-induced HDAC6 activation underlying AF progression. Our results demonstrate HDAC6-induced deacetylation of -tubulin to promote a shift from the polymerized microtubule structure towards the depolymerized form, which is susceptible to degradation by the protease calpain. Accordingly, in patients with PeAF, we found both activation of HDAC6 and deacetylation and degradation of -tubulin, which correlated inversely with calpain activity. These results indicate disruption of the mictrotubule structure in patients with PeAF. Disrupted microtubule structure causes reductions in contraction 32 , ICaL 33 , connexin 40 levels 9 and CaT amplitude 34 in cardiomyocytes, and might therefore also underlie AF progression. 3 The involvement of calpain is in accord with our previous observations that calpain is strongly activated during experimental and clinical AF 17, 19, 26 and with data showing degradation of brain -tubulin by calpain. 25 In addition to tubacin, the sirtuin inhibitor nicotinamide protected cardiomyocytes and Drosophila from tachypacing. It is conceivable that inhibition of deacetylation of -tubulin also underlies the protective effect of nicotinamide since tubacin and nicotinamide inhibit different HDACs that function in concert. 35 However, in contrast to previous reports 35 , nicotinamide did not prevent deacetylation and depolymerization of -tubulin. Other mechanism(s) may convey a protective effect of nicotinamide in AF, such as increased availability of NAD + . 36 It is unclear which member(s) of the sirtuin family mediate(s) the protective effects of nicotinamide. 37 Further research is warranted to elucidate the molecular mechanism(s) of nicotinamide mediated cardioprotection. While effective in a model of cardiac hyperthrophy 9 , the pan-HDAC inhibitors sodium butyrate and TSA proved ineffective in our models, in spite of their inhibition of deacetylation of -tubulin. Most likely, this beneficial effect of pan-HDAC inhibition in our AF models is offset by effects to increase acetylation of other proteins 38 such histone H4 (Supplementary Figure S7) .
Therapeutic implications
The efficacy of drugs presently used in AF is limited. 1 Thus, pharmacological approaches preventing or limiting the substrate for the promotion of AF ("upstream therapy") are warranted. 1 There are strong indications that loss of proteostatic control in cardiomyocytes represents an important substrate for the development and progression of AF. 3 The current study shows HDAC6-induced α-tubulin deacetylation and microtubule disruption to play a role in AF. Therefore, pharmacological inhibition of the major -tubulin deacetylating enzyme, HDAC6, represents a potentially promising target for upstream therapy. Since tubacin is not suitable for in vivo studies 39 , other HDAC6 inhibitors, such as tubastatin A and ACY-1215 have been developed, and show beneficial effects in mice models for neurodegenerative diseases and cancer. [39] [40] [41] In the current study, we provide the first evidence for the efficacy of HDAC6 inhibitors in AF by demonstrating tubastatin A to protect against atrial remodeling in tachypaced dogs. As the specific inhibition of HDAC6 has not been associated with any serious toxicity so far 30 , the current study suggests that HDAC6 is an interesting potential drug target for upstream therapy of AF.
Limitations of the study
Our notion that HDAC6 activation contributes to human AF is based on the analysis of patients with lone AF or AF originating from mitral valve disease. Whether HDAC6 activation also contributes to the etiology of AF of different origin needs to be established. Furthermore, although we obtained proof of concept of the beneficial effect of HDAC6 inhibition in AF, additional research should clarify if HDAC6 inhibition also reverses the structural remodeling of cardiomyocytes in AF. Japan). Osmotic pumps (2 ml with one-week delivery; Alzet, Cupertino, CA) filling with either 50% DMSO alone (for sham and ATP group) or tubastatin A in 50% DMSO were implanted subcutaneously. For ATP and ATP + tubastatin A groups, the pacemakers were turned on 24 hours after surgery to stimulate the RA at 600 bpm for 7 successive days. The ECG was checked daily to ensure AF during pacing. At the end of the study, all dogs were anesthetized with morphine (2mg/kg s.c.) and α-chloralose (120mg/kg i.v. bolus followed by 29.25mg/kg/hr i.v. infusion), intubated and ventilated. Body temperature was maintained at 37°C. After midline sternotomy, the pericardium was opened and 2 bipolar electrodes were fixed to the RA appendage (one for pacing, one for signal recording). For AF-induction, the RA was paced at 50 Hz for 3-10 seconds. A total of 5-10 AF episodes were recorded to calculate the mean AF duration in each dog. An AF episode >30 minutes was considered sustained, and the electrophysiological study was terminated. Cardioversion was avoided to prevent tissue damage, which precludes further cellular and molecular studies. In one sham dog, substantial electrophysiological derangements were observed at terminal study, including significant sinus node dysfunction and prolonged AF, as well as signs of senescence. These results could not be predicted at study initiation, because electrophysiological data were not obtained prior to the terminal study. The results of that dog were excluded for all analyses because of presumed underlying heart disease. To avoid bias due to exclusion from the sham group of a dog with prolonged AF, we also excluded from analysis the results of individual dogs with the longest-lasting AF in each of the other 2 groups (ATP+vehicle and ATP+tubastatin A).
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S1.2. Atrial cardiomyocyte isolation
After electrophysiological study, the heart was excised and immersed in oxygen- with an electronic shutter to minimize photo bleaching. Emitted light was reflected into a spectral separator, passed through parallel filters at 400 and 500 nm (±10 nm), detected by matched photomultiplier tubes, and electronically filtered at 60 Hz. 
S1.5. Slot Blotting and Western Blotting
Slot blot analysis was performed as described previously. 
S1.6. In vitro calpain mediated α-tubulin degradation assay
To measure α-tubulin degradation by calpain in vitro, α-tubulin was isolated from HL-1 cardiomyocytes by immunoprecipitation with non-denaturing lysis buffer (Tris HCl pH 8, 137 mmol/L NaCl, 10% glycerol, 1% Nonidet P-40 (NP-40), and 2 mmol/L EDTA). A/G beads (Santa Cruz) were coated with α-tubulin antibody (Sigma) to pull down α-tubulin from HL-1 cardiomyocyte lysate. To detach α-tubulin from the beads, the beads were incubated with elution buffer (0.2 mol/L glycine pH2.5) at room temperature for 10 min. After centrifugation, beads were removed and the eluate containing α-tubulin was transferred to a new tube, followed by adjustment to physiological pH by adding neutralization buffer (1mol/L Tris PH9.5, 1/10 v/v of elution buffer). To detect degradation of α-tubulin by calpain, calpain I (Merck/Calbiochem) was incubated with the same amount of α-tubulin eluate in reaction buffer (PBS with 2 mmol/L CaCl2) for 1 hour at room temperature. After incubation, loading buffer (10% SDS, 50% glycerol, 0.33mol/L Tris HCl pH=6.8, 10% betamercaptoethanol, 0.05% bromophenol blue) was added to the tube followed by 5 min boiling. Western blot analysis was used to detect α-tubulin.
S1.7. HDAC activity measurements
The overall HDAC activity was measured by utilizing a fluorimetric HDAC activity assay kit (Sigma) according to the manufacturer's instructions. Briefly, normal or tachypaced HL-1 cardiomyocytes or atrial tissue samples were lysed in non-denaturing buffer (CelLytic™ MT Cell Lysis Reagent, Sigma). Protein concentrations were determined by BioRad Protein Assay Kit (Bio-Rad). Fluorescence was measured with a fluorimeter (Bio-tek instruments FLx800) at 360nm excitation and 460nm emission wavelength. To test efficiency of HDAC inhibitors in HL-1 cardiomyocytes, lysates were incubated with the HDAC inhibitors as described in Table 1 . Blank samples and samples with HeLa cell nuclear extracts were used as negative and positive controls, respectively. Figure S1 : Efficacy of HDAC inhibitors to reduce overall HDAC activity in Drosophila. All the HDAC inhibitors significantly reduced HDAC activity at the concentrations used as described in Table 1 . *P<0.05 vs control, **P<0.01 vs control (without HDAC inhibitor). Table 1 and for niltubacin 1µM was used.
S2. Supplemental Figures
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Interview from Circulation
Circulation: Tell us about the key findings from this recent article in Circulation.
Authors: This article reveals that activation of a particular histone deacetylase (HDAC), HDAC6, conveys the structural and contractile remodeling in Atrial Fibrillation (AF). By utilizing atrial cardiomyocytes and Drosophila we found tachypacing to induce cardiomyocyte remodeling, which is dependent on the activation of a specific domain of HDAC6, called TDAC. Activation of TDAC leads to deacetylation of cytoplasmic alphatubulin and subsequent depolymerization and disruption of the microtubule network. Specific activation of HDAC6, in contrast to other HDACs, was also found in human biopsies from AF patients. Finally, we demonstrated that specific inhibitors of HDAC6, including tubacin and tubastatin A, attenuate cardiac remodeling in our experimental model systems and in tachypaced dogs, indicating HDAC6 as a druggable target for AF.
Circulation: What are the major implications of this work? Authors: Our work has several major implications. First, we identified novel druggable targets for AF therapy. Also, our research underscores the importance of derailment of proteostasis in cardiomyocyte remodeling and AF progression. Finally, the experimental model systems utilized, i.e. tachypaced atrial cardiomyocytes and Drosophila, substantiate the power of simple and easily genetically manipulated model systems in translational research.
Circulation: How did you get the idea to do this study?
Authors: Because of our previous studies on the cardioprotective role of heat shock proteins in AF, we were familiar with the knowledge on the role of cell proteostasis in health and disease. In addition, observations made in the lab of Eric Olson revealed a role for CaMKII in the phosphorylation and activation of HDAC4. Subsequently, activated HDAC4 caused deacetylation of contractile proteins and contractile dysfunction. As the CaMKII pathway is induced during AF and related to contractile dysfunction, we hypothesized that the HDACs might also be involved in AF. Luckily, this research proposal got funded by the Netherlands Heart Foundation.
Circulation: What were the biggest obstacle in completing this study?
Authors: The biggest obstacle was to identify the mechanism of the concomitant degradation of alpha-tubulin, that we observed in AF patients and tachypaced cardiomyocytes, and to demonstrate that this was actually caused by the tachypacing-
